Securities & Investment Fraud

Mallinckrodt plc Securities Class Litigation

Introduction

Securities fraud class action litigation has been filed on behalf of investors in Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK). If you purchased or otherwise acquired the securities of Mallinckrodt between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than March 27, 2017.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the actions. Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market. We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Mallinckrodt investors may choose to have Lieff Cabraser review their claim by completing the contact form below. You can also call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358 to discuss the litigation.

Background on the Mallinckrodt Securities Class Litigation

The action alleges that Mallinckrodt, an Irish pharmaceutical company, misrepresented and/or failed to disclose its dependence on Medicare and Medicaid reimbursements for revenues for its therapeutic andrenocorticotropic hormone (“ACTH” or “Acthar”) drugs used to treat infantile spasms and other conditions, and that it maintained a monopoly on Acthar treatments in the U.S., which threatened the sustainability of its reimbursement revenues.

On November 9, 2015, Citron Research (“Citron”) issued a statement on Twitter comparing Mallinckrodt to Valeant Pharmaceuticals, Inc., whose stock price had plummeted 30% after Citron accused Valeant of fraud. On this news, Mallinckrodt’s stock price fell 17%, to close at $58.01 per share.

On November 16, 2016, Citron published a report accusing Mallinckrodt and its Chief Executive Officer (“CEO”) of fraud in connection with the statements the CEO made downplaying the Company’s reliance on Medicare and Medicaid for Acthar revenue. The Citron report revealed that Medicare and Medicaid payments accounted for approximately 61% of the Company’s total Acthar revenue in 2015. On this news, the Company’s stock price fell 18.4%, to close at $55.32 per share.

On November 29, 2016, Mallinckrodt’s CEO disclosed on a conference call that Acthar represented “a significantly greater proportion of [the Company’s] operating income than one-third.” On this news, the Company’s stock price declined 9.1%, to close at $52.42 per share.

On January 18, 2017, the Federal Trade Commission and several states filed a lawsuit and simultaneously entered into a settlement with Mallinckrodt for $100 million for the Company’s anticompetitive conduct with respect to its Acthar pricing. On this news, the Company’s stock price fell 5.85% to close at $46.53 per share.


First Name (required)

Last Name (required)

Email address (required)

Street Address

City

State

Zip

Telephone Day

Telephone Eve

How did you find our site?

Are you currently represented by an attorney?

II. TRANSACTIONS IN MALLINCKRODT SECURITIES

Number of shares of Mallinckrodt securities held immediately before the start of the Class Period on November 25, 2014:

From November 25, 2014 through January 18, 2017, inclusive, I made the following transactions in Mallinckrodt securities:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

During the 90 days after January 18, 2017, I made the following transactions in Mallinckrodt securities:

SALES

Date
No. of Shares
Price

show more rows

Comments & questions:

Please sign me up for your Consumer Law newsletter. Yes
Please leave this field empty.


About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Best Lawyers and U.S. News have named Lieff Cabraser as a “Law Firm of the Year” for each year the publications have given this award to law firms.